The end of compounded versions of weight-loss drugs is near, leaving patients scrambling for alternatives. Some “copycat” ...

Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.

Eli Lilly is offering vials of its weight-loss drug Zepbound to patients at a discount — but only if they skip their ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to ...

The weight-loss drug can cost patients more than $1,000 a month if they do not have health insurance coverage.

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...

Last week, Eli Lilly, the maker of Zepbound, also cut prices for its starter dose to $349 per month. Larger doses will now cost $499 per month through the company’s self-pay program.

Wegovy’s maker, Novo Nordisk, is charging $499 per month for its direct-to-consumer product. Customers can’t get their health insurance to pay for the either Eli Lilly’s Zepbound vials or ...

The makers of two popular weight-loss drugs—Wegovy and Zepbound—are cutting prices to make the medications more affordable for people without insurance. Novo Nordisk, the Danish company behind Wegovy, ...